Tyra Biosciences, Inc. Segments Disclosure
12. Segment Information
The Company reports segment information based on the management approach, which reflects the way in which the internal reporting is used by the chief operating decision maker (CODM) to analyze performance, make decisions and allocate resources. The CODM is the Company’s .
The Company manages its operations as a reportable segment, which includes all activities related to the research, development, and potential future commercialization of its small molecule drug development candidates. The CODM assesses performance and decides how to allocate resources based on net loss (presented in the statements of operations and comprehensive loss). The measure of segment assets is reported on the balance sheets as total assets. All long-lived assets are located in the United States.
The table below shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, to the Company’s total net loss in the statements of operations and comprehensive loss (in thousands):
|
|
Year ended |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Research and development expenses: |
|
|
|
|
|
|
||
External research and development |
|
|
|
|
|
|
||
Dabogratinib (TYRA-300ACH) |
|
$ |
13,379 |
|
|
$ |
7,718 |
|
Dabogratinib (TYRA-300NMIBC) |
|
|
8,244 |
|
|
|
122 |
|
Dabogratinib (TYRA-300UTUC) |
|
|
2,440 |
|
|
|
— |
|
Dabogratinib (TYRA-300mUC) |
|
|
9,590 |
|
|
|
14,319 |
|
TYRA-430 |
|
|
9,055 |
|
|
|
5,677 |
|
TYRA-200 |
|
|
4,308 |
|
|
|
4,969 |
|
FGFR discovery |
|
|
10,967 |
|
|
|
8,199 |
|
Other development programs |
|
|
2,623 |
|
|
|
2,537 |
|
Unallocated research and development |
|
|
|
|
|
|
||
Personnel costs(1) |
|
|
36,218 |
|
|
|
30,423 |
|
Facilities and other costs(2) |
|
|
6,104 |
|
|
|
6,113 |
|
Total research and development expenses |
|
|
102,928 |
|
|
|
80,077 |
|
General and administrative expenses(3) |
|
|
29,834 |
|
|
|
24,100 |
|
Interest and other income, net |
|
|
(12,815 |
) |
|
|
(17,696 |
) |
Net loss |
|
$ |
(119,947 |
) |
|
$ |
(86,481 |
) |
(1) Personnel costs include $15.7 million and $14.3 million of stock-based compensation for the years ended December 31, 2025 and 2024, respectively.
(2) Facilities and other costs consist of research consumables, facility-related costs, depreciation and costs not attributed to a specific program.
(3) General and administrative expenses consist of personnel-related expenses, including stock-based compensation, legal fees, facility-related costs, depreciation, professional and consulting fees and insurance costs.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 2, 2026 | Showing above |
| 2024 | Mar 27, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.